Purchase Order N0017321P0319

<p>The Office of Naval Research awarded a purchase order to Illumina, Inc. valued at $31,592.90 on August 17, 2017. Place of performance is San Diego, California. The order is for firm fixed-price commercial biotechnology equipment or services, with ultimate completion scheduled for September 15, 2017. No small business set-aside was applied.</p>

The Office of Naval Research awarded a $5,675.74 firm fixed-price purchase order to Illumina, Inc. for laboratory supplies on May 5, 2017, with an ultimate completion date of August 3, 2017. The contract, issued without a set-aside designation, will be performed in San Diego, California, where Illumina maintains its headquarters. This purchase order represents a routine procurement of laboratory consumables and supplies from the biotechnology company, which specializes in genetic sequencing...

The Department of the Navy Secretary of the Navy Office of Naval Research has awarded a firm fixed price purchase order contract valued at two hundred thirty-one thousand two hundred ninety-two dollars ($231,292) to Illumina, Inc. to provide a NextSEQ1000 sequencing system. The place of performance will be in Washington, D.C. and the period of performance will conclude on November 22, 2023. No set-aside designation was used for this award. As the sole manufacturer of the proprietary sequencing...

<p>The Office of Naval Research awarded a purchase order to Illumina, Inc. for reagent kits valued at $9,495.20 on July 2, 2019, with completion by August 2, 2019. Place of performance is San Diego, California. The order is firm fixed price with no set-aside designation. No Service Contract Inventory reporting is present in the source.</p>

<p>The Office of Naval Research awarded a purchase order to Illumina, Inc. valued at $15,610.40 for reagent kits, with an award date of September 18, 2012 and ultimate completion date of October 9, 2012. Place of performance is San Diego, California. The order carries firm fixed-price pricing and no set-aside designation.</p>

The Office of Naval Research awarded a $16,302 firm fixed-price purchase order to Illumina, Inc. for reagent kits on September 26, 2013, with completion targeted for October 26, 2013. The contract, issued without a set-aside designation, will be performed in San Diego, California. Illumina is a biotechnology company specializing in genetic sequencing and genomic analysis technologies, providing DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software to federal...

<p>The Office of Naval Research issued a purchase order to Illumina, Inc. for MiSeq Reagent Kit V3 (600-cycle) valued at $14,272.59, awarded December 1, 2021, with completion by December 13, 2021. Performance occurs at Washington, DC 20375. The order is firm fixed price with no set-aside applied.</p>

This is a firm fixed price delivery order awarded by the Office of Administrative Services Procurement Management Branch, a civilian agency, to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The $98,056.80 order is for Illumina kits with no set-aside designation. Illumina has a history of providing sequencing systems and consumables to support genomic research and diagnostics across various federal agencies including NIH, CDC, USDA, and VA. This...

This is a $114,751.84 firm fixed price delivery order awarded by the Bureau of Medicine and Surgery, a component of the Department of the Navy, to Illumina, Inc. for the provision of various nucleic acid sequencing reagents and positive controls for Illumina sequencing instruments. The order is part of a larger $3.3 million Indefinite Delivery Contract held by Illumina with the Navy Bureau of Medicine and Surgery to support nucleic acid sequencing needs, including for characterizing biological...

This is a firm fixed price delivery order awarded by the National Institutes of Health (NIH) Clinical Center to Illumina, Inc. for the provision of Illumina reagent kits. The order, valued at $52,407.45, has a period of performance through September 30, 2024. There was no set-aside designation for this award. Based on Illumina's prior federal contract work, the company has provided a range of genomic sequencing instruments, reagents, and related services to support research and diagnostics...